Journal of Psychoactive Drugs
September 1, 2026
Brian P. Meier, Courtney M. Lappas, Matthew W. Johnson
= 1,102), we examined the intentions to use psilocybin in a mental health context in relation to psychotherapy, psychiatric medication, and natural versus synthetic options. We also examined potential predictors of the intentions to use psilocybin. In Study 1, we found that participants had significantly lower intentions to use psilocybin in a mental health context versus psychotherapy and...
Psychiatry International
September 1, 2026
Damian Swieczkowski, Michal Pruc, Lukasz Szarpak et al.
Major depressive disorder (MDD) and treatment-resistant depression (TRD) continue to drive interest in ketamine-family compounds and psilocybin, but antidepressant efficacy alone does not establish whether these interventions can be evaluated reliably or implemented responsibly. We conducted a structured narrative review using targeted PubMed/MEDLINE searches through 21 July 2026,...
Frontiers in Psychiatry
September 1, 2026
Gabrielle Agin-Liebes, Sarah Shnayder, Geena Fram et al.
Introduction Psilocybin treatment has shown promise for treatment-resistant obsessive-compulsive disorder (OCD), yet clinical response is variable. Little is known about the subjective experiences associated with divergent outcomes or the psychological processes differentiating responders from non-responders. Materials and methods A qualitative case comparison was conducted using...
Neuropsychopharmacology Reports
September 1, 2026
Daisuke Ibi, Rika Takaba, Keisuke Yoshida et al.
Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) exert hallucinogenic effects through stimulation of serotonin 5-HT2A receptors (5-HT2ARs) in the cerebral cortex. In recent years, numerous reports have demonstrated that psychedelics are effective in treating various psychiatric disorders such as major depressive disorder (MDD), treatment-resistant depression (TRD), and...
International Journal of Innovative Technologies in Social Science
August 31, 2026
Katarzyna Pawłucka, Aleksandra Pawlucka, Joanna Kadłuczka et al.
Objectives: This narrative review synthesizes current evidence regarding the modulation of psilocybin responsivity by female sex hormones (estrogen, progesterone, testosterone) across the lifespan, aiming to identify molecular mechanisms, clinical implications, and critical knowledge gaps for personalized psychedelic medicine. Methods: Databases including PubMed, ClinicalTrials.gov, and ANZCTR...
Zenodo (CERN European Organization for Nuclear Research)
August 31, 2026
preprint
Evidence for psilocybin use in chronic depression is limited, primarily focusing on treatment-resistant cases. While promising results have been noted in studies, more targeted and extensive research is needed.
Psychoactives
August 30, 2026
Laura Schäffert, Human-Friedrich Unterrainer
Background: Alcohol use disorder (AUD) remains a leading contributor to global morbidity, yet conventional treatments often yield suboptimal outcomes and high relapse rates. Psilocybin-assisted therapy has re-emerged as a potential intervention for substance use disorders, but its effectiveness and safety in AUD specifically remain to be comprehensively evaluated. Objective: To review and...
Journal of Psychopharmacology
August 30, 2026
Tiffini N Lovell, Peter B James, Skylar L Hodgins et al.
Fentanyl is the leading cause of fatal overdoses worldwide, and repeated use may lead to substance use disorder (SUD). In SUD, drug-associated contexts can trigger reward-related behavior even in the absence of the drug. Psychedelic compounds may weaken context-drug associations, reducing reward-related behavior to fentanyl. We evaluated the effects of the psychedelic psilocin and its...
Journal of Psychopharmacology
August 29, 2026
Marlene Tai, Balázs Szigeti, Amanda E. Downey et al.
BACKGROUND Psilocybin, a serotonergic psychedelic found in hallucinogenic mushrooms, is metabolized to psilocin, the compound responsible for its psychoactive effects. Psilocybin has demonstrated therapeutic potential for neuropsychiatric conditions. While recent trials have primarily used orally administered synthetic psilocybin, alternative formulations and delivery methods may offer...
Zenodo (CERN European Organization for Nuclear Research)
August 28, 2026
Luna da Silva Nascimento
preprint
Independent secondary computational research conducted on open-access longitudinal fMRI data (OpenNeuro ds006072). Preprint deposited on Zenodo. Full reproducible Riemannian pipeline available on GitLab.